Staphylococcus aureus MRSA (BAA-1717), Dermal Infection Model, CFU Data
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model evaluates the antimicrobial efficacy of test articles for treatment of superficial skin infections with a community acquired MRSA. USA300 S. aureus is a community-associated epidemic MRSA that causes rapidly progressive and fatal diseases. This strain, originally named TCH1516, is resistant to erythromycin and most classes of beta-lactam antibiotics. It is susceptible to quinolones, vancomycin, daptomycin, linezolid, and carbapenems.
SPECIES
Staphylococcus aureus
ORGANISM
Gram-positive Bacteria
INCUBATION CONDITIONS
Aerobic
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 immune competent mice are used. The animals are anesthetized, the fur on the back is removed with an electric shaver, and the epidermal layer is disrupted with an abrasive paper. Infection is initiated by placing a 5 μL droplet containing 1 x 10⁵ cells of Staphylococcus aureus (BAA-1717) on the wound area. Test article is administered at timepoints after infection. Vehicle and/or test substances are then administered 1 and 13 hours later per the specification of the study design table. The animals are euthanized by CO₂ asphyxiation at 25 hours after inoculation. The skin of wound infection (2 cm²) is excised and is homogenized with 1 mL of PBS. Homogenates, 0.1 mL aliquots, are used for serial 10-fold dilutions and plated on nutrient agar for bacterial counts.
CRITERIA FOR SIGNIFICANCE
A significant (p < 0.05) decrease in the bacterial counts of the treated animals compared to the vehicle control group or the baseline control group was considered a significant difference.
TURNAROUND TIME
STANDARD
25 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences